STOCK TITAN

Certara, Inc. - CERT STOCK NEWS

Welcome to our dedicated page for Certara news (Ticker: CERT), a resource for investors and traders seeking the latest updates and insights on Certara stock.

Certara, Inc. (NASDAQ: CERT) is a leading provider of decision support technology and consulting services designed to optimize drug development and improve health outcomes. The company's suite of solutions spans the entire drug development and patient care lifecycle, employing advanced modeling and simulation technologies along with cutting-edge regulatory strategies. Certara's services are pivotal in increasing the probability of both regulatory and commercial success for their clients, which include over 2,300 global biopharmaceutical companies, leading academic institutions, and major regulatory agencies across 70 countries.

Certara's core business revolves around leveraging biosimulation software and technology to transform traditional drug discovery and development processes. By using its innovative modeling and simulation tools, the company aids clients in reducing the need for extensive clinical trials, thereby accelerating regulatory approvals and enhancing patient access to new therapies. Their product suite includes regulatory science, assessment software, and a range of consulting services, all aimed at streamlining drug development.

One of Certara's notable achievements is its collaboration with the FDA on physiologically-based pharmacokinetic (PBPK) modeling for virtual bioequivalence (VBE) and predicting drug absorption of topical formulations. These initiatives aim to replace costly and time-consuming clinical bioequivalence studies with efficient virtual simulations, thus speeding up the development process and reducing costs. The Simcyp Simulator, a key component of Certara's technology, has already proven its utility in replacing clinical studies in VBE and dermal absorption scenarios.

Certara's business operations are primarily concentrated in the Americas, generating significant revenue from this region, with additional market presence in EMEA and the Asia Pacific. The company continues to expand its software portfolio with innovations like the Simcyp™ Biopharmaceutics software, which helps drug developers optimize formulations for complex therapies, and the recently launched Certara Cloud, a unified platform that integrates their scientific software solutions for seamless workflow management.

Financially, Certara has reiterated its full-year guidance for 2024, showcasing a stable outlook and ongoing commitment to delivering high-quality, innovative solutions. Their recent acquisition of Applied BioMath underscores their growth strategy, enhancing their capabilities in quantitative systems pharmacology (QSP) to de-risk and accelerate therapeutic R&D. The combined expertise positions Certara as the largest QSP center of excellence, further strengthening their role in the life sciences industry.

For more information, visit www.certara.com.

Rhea-AI Summary

Certara, a leader in model-informed drug development, has signed a definitive agreement to acquire cheminformatics software provider Chemaxon. The acquisition is expected to close in the second half of 2024, pending regulatory approvals. This deal aims to enhance Certara's drug discovery capabilities by integrating Chemaxon's software, which is important for chemical structure drawing, property prediction, and analysis.

Chemaxon is projected to generate over $20 million in software revenue in 2024 and is expected to align with Certara’s EBITDA margin by the end of 2025. The combined entity will offer a comprehensive data and predictive analytics platform, expected to improve decision-making and reduce costs in drug development.

Certara has reiterated its full-year 2024 financial outlook, excluding Chemaxon, and will update its guidance post-transaction, maintaining an adjusted EBITDA margin of 31-33%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
-
Rhea-AI Summary

Certara (Nasdaq: CERT), a global leader in model-informed drug development, will announce its Q2 2024 financial results after market close on August 6th, 2024. The announcement will be followed by a conference call at 5:00 PM ET to discuss the results. Investors are advised to register online for the call at least a day in advance. The event will be broadcast live and archived on Certara's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
conferences earnings
-
Rhea-AI Summary

Certara (Nasdaq: CERT) has launched its next-generation CoAuthor regulatory writing software, enhancing the medical writing process using generative AI. Unveiled on June 17, 2024, CoAuthor integrates AI, document templates, and Microsoft Word, aiming to expedite the creation of regulatory documents while maintaining a 'human in the loop' approach. The software allows medical writers to efficiently synthesize complex biomedical data, providing a secure and specialized GPT for the drug development sector.

The platform promises to improve drafting times by at least 30%, enhancing content curation and quality control. Certara’s CEO, William Feehery, emphasized the company's expertise in maximizing AI’s potential in drug development. CoAuthor will be presented at the DIA Annual Meeting in San Diego, featuring a dedicated session on June 17th.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.49%
Tags
AI
Rhea-AI Summary

Certara (Nasdaq: CERT), a global leader in biosimulation, announced its participation in the Jefferies Global Healthcare Conference.

The event will take place on June 5th, 2024, at 11:30AM ET.

Company management will present at the conference, and a live webcast will be available on Certara’s investor relations website.

The webcast replay will be accessible for at least 90 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.49%
Tags
conferences
-
Rhea-AI Summary

On May 21, 2024, Certara (Nasdaq: CERT), a global leader in model-informed drug development, announced the appointment of Rona Anhalt as Chief Human Resources Officer and Daniel Corcoran as General Counsel.

CEO William F. Feehery expressed confidence in their ability to enhance Certara's mission to accelerate medicine development. Anhalt, previously with EQRx, will lead human capital management for Certara's 1,400 employees, including 400 scientists. Corcoran, coming from Nexthink, will oversee legal affairs, bringing over 20 years of experience from technology companies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
management
-
Rhea-AI Summary

Certara, Inc. reported its first quarter 2024 financial results, with revenue reaching $96.7 million, a 7% increase from the previous year. Software revenue grew by 19% to $39.3 million, while services revenue remained flat. The net loss was $4.7 million, with adjusted EBITDA at $29.1 million. The company reiterated its full-year 2024 financial guidance, expecting revenue between $385 million to $400 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.42%
Tags
Rhea-AI Summary
Certara, Inc. launches Certara Cloud, a platform integrating its scientific software solutions for model-informed drug development. The platform aims to enhance customer experience, streamline workflows, and provide real-time collaboration and security benefits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
none
-
Rhea-AI Summary
Certara, Inc. (CERT) will release Q1 2024 financial results on May 7th, 2024, followed by a conference call at 5:00PM ET. The company will also participate in the BofA Securities Healthcare Conference on May 14th. Live and archived webcasts will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
conferences earnings
-
Rhea-AI Summary
Certara, Inc. provides full-year 2024 financial guidance, reporting $88.0 million in revenue for the fourth quarter of fiscal year 2023, a 2% increase over the previous year. The net loss was $12.5 million due to increased operating expenses and fair value adjustments. The company aims to grow in 2024 with investments in new software products and artificial intelligence capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.41%
Tags
Rhea-AI Summary
Certara, Inc. (CERT) will release its financial results for Q4 and full year 2023 on February 29th, 2024. The company will also participate in the Barclays 26th Annual Global Healthcare Conference on March 13th. Live and archived webcasts will be available on the Certara website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
conferences earnings

FAQ

What does Certara, Inc. specialize in?

Certara specializes in decision support technology and consulting services for optimizing drug development and improving health outcomes using advanced modeling and simulation technologies.

Who are Certara's clients?

Certara's clients include over 2,300 biopharmaceutical companies, academic institutions, and key regulatory agencies across 70 countries.

What is the Simcyp Simulator used for?

The Simcyp Simulator is used for virtual bioequivalence studies and predicting drug absorption, replacing costly clinical trials in the process.

What are some recent achievements of Certara?

Certara has collaborated with the FDA on PBPK modeling, launched the Simcyp™ Biopharmaceutics software, and introduced Certara Cloud for integrated scientific workflow management.

In which regions does Certara operate?

Certara operates primarily in the Americas, with additional presence in EMEA and the Asia Pacific region.

How does Certara help in drug development?

Certara helps in drug development by providing modeling and simulation tools, regulatory science services, and assessment software to reduce clinical trials, accelerate regulatory approvals, and increase patient access to medicines.

What is Certara Cloud?

Certara Cloud is a unified platform that integrates Certara's scientific software solutions, providing clients a seamless experience for managing their drug development workflows.

What is the significance of Certara's acquisition of Applied BioMath?

The acquisition of Applied BioMath enhances Certara's capabilities in quantitative systems pharmacology (QSP), making them the largest QSP center of excellence and improving their ability to de-risk and accelerate drug R&D.

Who are some of Certara's key partners and collaborators?

Certara collaborates with global regulatory agencies like the FDA and works closely with biopharmaceutical companies and academic institutions.

Where can I find more information about Certara?

More information about Certara can be found on their official website at www.certara.com.

Certara, Inc.

Nasdaq:CERT

CERT Rankings

CERT Stock Data

2.59B
160.84M
3.02%
99.26%
2.73%
Software Publishers
Information
Link
United States of America
PRINCETON